# Immunogenicity and Safety of ADACEL™ as Fifth Dose in Taiwan

> **NCT00258908** · PHASE3 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 115 (actual)

## Conditions studied

- Diphtheria
- Tetanus
- Pertussis

## Interventions

- **BIOLOGICAL:** Diphteria, tetanus, and Acellular Pertussis vaccine

## Key facts

- **NCT ID:** NCT00258908
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11
- **Primary completion:** 2006-08
- **Final completion:** 2006-08
- **Target enrollment:** 115 (ACTUAL)
- **Last updated:** 2016-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00258908

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00258908, "Immunogenicity and Safety of ADACEL™ as Fifth Dose in Taiwan". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00258908. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*